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Mesenchymal stem cells are stromal progenitors of 
the mesodermal lineage
Mesenchymal stem cells (MSCs) are a heterogeneous 
subset of stromal stem cells that can be isolated from 
many adult connective tissues. Th   e cells grow as plastic-
adherent ﬁ   broblast-like cells that proliferate in vitro, 
maintaining pluripotency after prolonged culture. Under 
appropriate stimulus, MSCs can diﬀ  erentiate in vitro and 
in vivo into cells of the mesodermal lineage, such as bone, 
fat and cartilage cells.
MSCs have mainly been characterized after isolation 
from the bone marrow, where they are likely to represent 
the precursor cells for stromal tissue in close physical 
association with hematopoietic stem cells involved in 
hematopoiesis and maintenance of the homeostasis of 
the hematopoietic stem cell niche [1]. In the bone 
marrow the existence of a population of neural-crest-
derived stem cells was also shown, thus providing an 
expla  nation for the reported ability of bone-marrow-
derived stem cells to also generate, to some extent, neural 
cells [2].
Despite evidence showing that MSCs can trans  diﬀ  er-
entiate into multiple cell types in vitro and in vivo, the 
real contribution of MSCs to tissue repair – through 
signi ﬁ  cant engraftment and diﬀ  erentiation into biologi-
cally and functionally relevant tissue-speciﬁ  c cell types – 
is still elusive [3]. In the bone marrow, MSCs provide a 
sheltering microenvironment contributing to the preser-
va  tion of hematopoietic stem cells by shielding them 
from diﬀ  erentiation and apoptotic stimuli and regulating 
their quiescence, proliferation and diﬀ  erentiation. Owing 
to their ability to support hematopoiesis, MSCs were ﬁ  rst 
utilized to enhance immune reconstitution when 
transplanted together with hematopoietic stem cells. Th  e 
translation of the capacity of MSCs to diﬀ  erentiate into 
other tissues was ﬁ  rst exploited for reparative purposes, 
for example, in bone and heart diseases. Th  e  observation 
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Stem cells are currently seen as a treatment for 
tissue regeneration in neurological diseases such as 
multiple sclerosis, anticipating that they integrate 
and diff  erentiate into neural cells. Mesenchymal 
stem cells (MSCs), a subset of adult progenitor cells, 
diff  erentiate into cells of the mesodermal lineage 
but also, under certain experimental circumstances, 
into cells of the neuronal and glial lineage. Their 
clinical development, however, has been signifi  cantly 
boosted by the demonstration that MSCs display 
signifi  cant therapeutic plasticity mainly occurring 
through bystander mechanisms. These features 
have been exploited in the eff  ective treatment of 
experimental autoimmune encephalomyelitis, an 
animal model of multiple sclerosis where the inhibition 
of the autoimmune response resulted in a signifi  cant 
amelioration of disease and decrease of demyelination, 
immune infi  ltrates and axonal loss. Surprisingly, these 
eff  ects do not require MSCs to engraft in the central 
nervous system but depend on the cells’ ability to 
inhibit pathogenic immune responses both in the 
periphery and inside the central nervous system and 
to release neuroprotective and pro-oligodendrogenic 
molecules favoring tissue repair. These results paved 
the road for the utilization of MSCs for the treatment of 
multiple sclerosis.
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proliferation  in vitro [4] and in vivo [5], however, 
unexpectedly drove attention to their exploitation for the 
treatment of immune-mediated diseases; for example, in 
those diseases where their ability of modulating the 
immune response could combine with the ability to 
integrate into damaged tissues and foster repair. Experi-
mental autoimmune encephalo  myelitis (EAE), a model 
for multiple sclerosis, has been the ﬁ  rst  experimental 
autoimmune disease success  fully treated with MSCs [6].
Experimental autoimmune encephalomyelitis is an 
example of immune-mediated disease
EAE can be actively induced in susceptible inbred 
rodents by immunization with diﬀ  erent neural antigens 
mainly derived from myelin, including myelin basic 
protein, proteolipid protein (PLP) and myelin oligo-
dendro  cyte protein (MOG) in complete Freud’s adjuvant. 
Disease induction with PLP in SJL mice, and likewise 
MOG in C57BL/6 mice, requires the use of pertussis 
toxin that facilitates immune cell entry into the central 
nervous system (CNS) and contributes to T-cell tolerance 
breaking. EAE can be also induced in naïve mice by the 
intravenous passive transfer of encephalitogenic myelin-
speciﬁ  c T cells. In fact, EAE is considered a prototypical 
MHC class-II-restricted CD4+ T-cell-mediated disease. 
During the induction phase, myelin-reactive CD4+ T cells 
are primed and expanded in the peripheral lymphoid 
organs. Th  e  eﬀ  ector phase involves migration of activated 
myelin-speciﬁ  c T cells to the CNS, where they cross the 
blood–brain barrier and require myelin peptides 
presented by local antigen-presenting cells and dendritic 
cells for full reactivation [7].
Several lines of evidence indicate that many subsets of 
T cells play diﬀ  erent roles in the onset, maintenance and 
recovery of EAE, T-helper-type 17 cells and regulatory 
T cells being among the main contributors to the ﬁ  nal 
outcome [8]. Not only T cells but also B cells producing 
demyelinating antibodies and macrophages are key 
eﬀ  ector cells in EAE pathogenesis. Typical EAE lesions 
resemble patterns of demyelination, inﬂ  ammatory  cell 
perivascular inﬁ  ltrates, reactive microgliosis and astro-
cytosis, observed in multiple sclerosis lesions [9].
Systemic eff  ect of the intravenous delivery 
of mesenchymal stem cells in experimental 
autoimmune encephalomyelitis
In the study by Zappia and colleagues we demonstrated 
that intravenous injection of syngeneic MSCs into 
C57BL/6 mice immunized with peptide 35 to 55 of MOG 
signiﬁ   cantly improved the clinical severity of EAE, in 
parallel decreasing CNS inﬂ  ammation and demyelination 
[6]. More impor  tantly, we demonstrated that one 
injection of MSCs at disease onset or at the peak of 
disease suﬃ   ces to induce peripheral tolerance, as demon-
strated by the inability of T  cells isolated from lymph 
nodes of MSC-treated mice, but not from control 
animals, to proliferate when stimulated with the 
immunizing antigen MOG. We also observed a dose-
dependent eﬀ   ect that reached maximum eﬃ   cacy  and 
negligible mortality at the dose of 1  ×  106 MSCs. No 
clinical eﬀ  ect was observed when MSCs were infused 
during the chronic phase of EAE, suggesting that multiple 
injections may not provide further advantages if 
permanent tissue damage has occurred [6]. In another 
study, Zhang and colleagues demonstrated that intra-
venous administration of human MSCs could improve 
the clinical course of PLP-induced EAE in SJL mice 
through some level of engraftment in the CNS and subse-
quent release of neurotrophic factors promoting oligo-
dendrogenesis [10]. Th   ese results highlighted that MSCs 
can cross MHC boundaries and exert their therapeutic 
eﬀ   ect also in the CNS, regardless of a very limited 
engraft  ment. Following these pioneer works, in the last 
years several studies have focused on the mechanisms 
underlying the therapeutic eﬀ  ect of MSC transplantation 
on EAE.
Th  e concept that MSCs ameliorate EAE through the 
induction of peripheral immune tolerance was further 
nourished by the demonstration that intravenous admin-
is  tration of allogeneic MSCs in PLP-immunized mice 
inhibits the production of myelin-speciﬁ  c  antibodies 
compared with controls [11]. In addition, the exposition 
of encephalitogenic T cells to MSCs in vitro signiﬁ  cantly 
decreases their ability to passively transfer EAE to healthy 
syngeneic mice [11]. Many other studies have conﬁ  rmed 
that MSCs can modulate the peripheral immune 
response to myelin antigens [12-19]. Th  ese  in vivo results 
have been corroborated by detailed in vitro studies 
dissecting the mechanisms of action of MSCs on 
T  lymphocytes, B lymphocytes, dendritic cells, natural 
killer cells and other immune cells [20].
Mesenchymal stem cells are neuroprotective
It is important to underline that eﬀ  ects of MSCs on EAE 
are not exclusively due to their immunomodulatory 
activity, as many groups have shown that MSCs can also 
protect neurons and spare axons with no or very limited 
evidence of engraftment and/or transdiﬀ  erentiation into 
neural cells [11-13,15,16,21].  Th  ese ﬁ   ndings posed the 
question of whether the observed neuroprotection in 
EAE is due to the peripheral eﬀ   ects suppressing the 
immune response that damages myelin or to a direct 
protective and reparative activity that follows their 
engraftment in the CNS.
Several lines of evidence suggest that, somehow, MSCs 
have a direct eﬀ  ect on neural cells. Th   ey have been shown 
to enhance remyelination in vivo [15,16], provide in vitro 
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Page 2 of 7Figure 1. Local mesenchymal stem cell administration does not provide signifi  cant advantage compared with systemic infusion. 
(a) Clinical course of peptide 33 to 55 of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) in 
C57Bl6 mice after intrathechal (i.t.) or intravenous (i.v.) mesenchymal stem cell (MSC) injection. Arrow, day of injection. *P ≤0.05 Mann–Whitney 
U test. (b) Analysis of demyelination in the spinal cord of treated mice; 5 μm sections were stained with Luxol Fast Blue and the demyelinated 
area was expressed as a percentage of the total surface area. *P ≤0.01 Mann–Whitney U test. (c) Counts of luciferase-labeled MSCs in the central 
nervous system (CNS) of EAE-aff  ected mice. Luciferase-positive MSCs were detected using a rabbit anti-luciferase monoclonal antibody (Alexa Fluor 
488-conjugated) after 24 hours and 40 days from intravenous and intratechal injection. Six CNS tissue sections per mouse were analyzed and in 
each section the number of positive cells was reported as the number of positive elements/mm2.
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cells [16,22], display a potent antioxidant eﬀ  ect in vivo 
[23,24] and display a neuroprotective eﬀ  ect [25] mediated 
by the release of antiapoptotic molecules in vitro [26] and 
in vivo [27]. Th  ese neuroprotective eﬀ  ects may well ex-
plain the remarkable eﬀ  ect obtained with the adminis-
tration of MSCs in experimental models of stroke [28] 
and spinal cord injury [29]. Th   ere is uncertainty, however, 
regarding the ability of MSCs to colonize the CNS after 
peripheral delivery due to their scarce ability to pass the 
lung ﬁ  lter following intravenous administration [30] and 
due to the lack of reliable labels or deﬁ  nitive markers for 
MSCs [31].
Irrespective of these aspects, the current view suggests 
that MSCs may exert their neuroprotective eﬀ  ect  at 
distance through the release of trophic molecules, 
possibly aﬀ  ecting microglia activation [27] and inducing 
local neurogenesis [15,16,32].
Does local administration provide signifi  cant 
advantage compared with systemic infusion?
To enhance the possibility for MSCs to engraft in the 
CNS and provide optimal therapeutic eﬀ  ects  locally, 
Kassis and colleagues demonstrated, following intra-
ventricular injection of MSCs, the expression of neural 
markers by a few transplanted labeled cells mainly in the 
proximity of inﬂ  ammatory lesions – suggesting that some 
level of transdiﬀ  erentiation was achieved [12]. Similarly, 
Barhum and colleagues showed that intraventricular 
adminis tration  in vitro of MSCs modiﬁ   ed to produce 
neuro  trophins successfully attenuated EAE [19].
We therefore evaluated whether local injection of a 
high number of MSCs may provide some advantage over 
intravenous systemic administration by comparing two 
diﬀ  erent routes of cell delivery in C57Bl/6 mice following 
immunization with the myelin antigen, peptide 35 to 55 
of MOG. Th   e intratechal delivery of 1 × 106 MSCs at the 
onset of the ﬁ   rst clinical symptoms (around day 10) 
resulted in a signiﬁ  cant amelioration of EAE compared 
with intra  techally PBS-injected animals. No signiﬁ  cant 
diﬀ  erence was observed, however, when we compared 
the clinical course of mice intravenously injected with 
those treated intratechally (Figure  1 and Table  1). No 
signiﬁ  cant diﬀ  er  ence was also observed when the extent 
of spinal cord demyelinating lesions was compared 
(Figure 1). As expected, the number of Luciferase-
transfected MSCs, detected after 24 hours in the CNS of 
intratechally injected mice, was higher than in those 
where MSCs were delivered intravenously. After 40 days, 
however, the number of Luciferase-positive cells was 
clearly diminished with no statistical diﬀ  erence between 
the two groups (Figure 1). Th   ese results favor the current 
hypo  thesis that MSCs act by diﬀ  erent  mechanisms, 
mainly paracrinally on cells both at a distance and at the 
site of tissue damage, without the requirement of long-
term engraftment [33].
Intravenous injection of mesenchymal stem cells 
also modulates the immune response in the CNS
A major issue still unsolved by the above-described 
studies was whether intravenously injected MSCs could 
also impact the immune response inside the CNS. It is 
well known that, following intravenous administration, 
MSCs inhibit inﬁ  ltration of T cells and macrophages in 
mice with EAE [6]. Th   ese results, however, are likely to be 
an eﬀ  ect of the cells’ tolerogenic ability exerted in the 
periphery on encephalitogenic T cells, as demonstrated 
by the inhibition of EAE following passive transfer of 
myelin-speciﬁ  c T cells [11].
To address this question we isolated T cells inﬁ  ltrating 
the brain of EAE-aﬀ   ected mice treated either intra-
venously or intratechally with MSCs and we measured by 
intracellular ﬂ   ow cytometry and real-time PCR the 
expression of the transcription factor FOXP3, a speciﬁ  c 
marker of regulatory T cells previously demonstrated to 
be  expanded in the lymphoid organs of mice with 
collagen-induced arthritis treated with MSCs [34]. We 
observed not only that the intratechal delivery of MSCs 
induced an expansion of FoxP3+ T cells in the brain of 
EAE-aﬀ  ected mice compared with controls, but also that 
a similar result was observed in intravenously injected 
mice (Figure  2). Such a result probably depends on 
increased recruitment of this subset from the peripheral 
blood. To our surprise we observed, in the T cells isolated 
from the brain of both groups of MSC-treated mice 
compared with controls, an increase in the expression of 
Table 1. Clinical features of experimental autoimmune encephalomyelitis-aff  ected mice
  Disease  Disease onset,   Mean maximum  Cumulativ  e
  incidence  days after immunization  neurologic score  disease score
EAE control i.v.  14 / 14 (100%)  12 ± 0.8  3 ± 0.5  84.4 ± 13
EAE + MSCs i.v.  14 / 15 (93.4%)  11.5 ± 0.5  2.5 ± 0.9  67.6 ± 28.7*
EAE control i.t.  14 / 14 (100%)  11.6 ± 0.6  3 ± 0.5  85.2 ± 15.3
EAE + MSCs i.t.  14 / 15 (93.4%)  12.3 ± 1  2.4 ± 0.7*  63.7 ± 25.7*
Data presented as n / total (%) or mean ± standard deviation. EAE, experimental autoimmune encephalomyelitis; i.t., intrathecally; i.v., intravenously; MSC, 
mesenchymal stem cell. *P ≤0.05 (Student’s t test).
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Page 4 of 7Figure 2. Intratechal and intravenous injection of mesenchymal stem cells modulates immune response in central nervous system. 
Expression of FoxP3 in T cells infi  ltrating the central nervous system of experimental autoimmune encephalomyelitis aff  ected mice at the peak of 
disease: (a) at protein level, evaluated by intracellular fl  ow cytometry (FACSCanto II; BD Bioscience, Buccinasco, Milan, Italy); and (b) at mRNA level, 
evaluated by real-time PCR using a LightCycler® 480 (Roche Applied Science, Indianapolis, IN, USA). (c) IL-17 mRNA expression from infi  ltrating 
T cells, analyzed by real-time PCR. *P ≤0.05 Mann–Whitney U test. i.v., intravenous; i.t. intrathecal.
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pathogenesis of autoimmune diseases (Figure 2). Th  ese 
results may be explained by the recent demonstration 
that MSCs can induce T-helper-type 17 cells to acquire a 
regulatory phenotype [35], and may also clarify the 
observation that human MSCs were shown to increase T-
helper-type 17 responses in vitro [36].
Conclusions
Overall, many studies have conﬁ  rmed that MSCs, either 
from syngenic or xenogeneic sources, are eﬀ  ective in the 
treatment of EAE and dissected their mechanisms of 
action, probably in a much deeper fashion than in any 
other experimental disease. Th   e results discussed in the 
present article demonstrate that MSCs can repair neural 
tissues as they display a broad therapeutic activity that 
acts both on immune and neural cells but feebly involves 
their transdiﬀ  erentiation. Interestingly, despite a limited 
ability to engraft in the nervous system, MSCs can clearly 
modulate the immune response not only in the peripheral 
lymphoid organs [6] but also within the CNS.
Based on these studies and the available clinical experi-
ence obtained in several human conditions, MSCs can be 
considered an appealing therapeutic option for multiple 
sclerosis individuals with ongoing inﬂ  ammatory disease   
refractory to conventional therapies [37,38].
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